{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=omalizumab&page=2",
    "query": {
      "intervention": "omalizumab",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=omalizumab&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T10:26:05.403Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03580356",
      "title": "A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Ligelizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1078,
      "start_date": "2018-10-20",
      "completion_date": "2022-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580356"
    },
    {
      "nct_id": "NCT01264939",
      "title": "A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Idiopathic Urticaria"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 336,
      "start_date": "2011-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2013-11-26",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 40,
      "location_summary": "Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Napa",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264939"
    },
    {
      "nct_id": "NCT02023151",
      "title": "Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 17,
      "start_date": "2013-02",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02023151"
    },
    {
      "nct_id": "NCT04180488",
      "title": "Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Dupilumab SAR231893",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "non sedating H1-antihistamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "6 Years to 80 Years"
      },
      "enrollment_count": 397,
      "start_date": "2019-12-11",
      "completion_date": "2024-10-25",
      "has_results": true,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Sweetwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04180488"
    },
    {
      "nct_id": "NCT01290913",
      "title": "Xolair Enhances Oral Desensitization in Peanut Allergic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lynda Schneider",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "7 Years to 25 Years"
      },
      "enrollment_count": 13,
      "start_date": "2011-02",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290913"
    },
    {
      "nct_id": "NCT04128176",
      "title": "Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "Rituximab combined with Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-03",
      "completion_date": "2023-11-25",
      "has_results": false,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04128176"
    },
    {
      "nct_id": "NCT02966314",
      "title": "Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Idiopathic Angioedema"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-03-30",
      "completion_date": "2020-01-06",
      "has_results": true,
      "last_update_posted_date": "2022-11-01",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02966314"
    },
    {
      "nct_id": "NCT01040598",
      "title": "Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "O & O Alpan LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "12 Years to 76 Years"
      },
      "enrollment_count": 19,
      "start_date": "2009-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-03-14",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 1,
      "location_summary": "Springfield, Virginia",
      "locations": [
        {
          "city": "Springfield",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01040598"
    },
    {
      "nct_id": "NCT01701583",
      "title": "Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Urticaria"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2013-04",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01701583"
    },
    {
      "nct_id": "NCT04943744",
      "title": "Gastrointestinal STRING Test With Oral Immunotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Eosinophilic Disorder",
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "Entero-tracker",
          "type": "DEVICE"
        },
        {
          "name": "omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dupliumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "5 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-05-17",
      "completion_date": "2024-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-25T10:26:05.403Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04943744"
    }
  ]
}